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Perspective
Ovarian Cancer: A Clinical Challenge 
That Needs Some Basic Answers
Kate Lawrenson, Simon A. Gayther*
From a clinical perspective, epithelial ovarian cancer is something of an enigma. 
Despite improvements in aggressive 
debulking surgery and the initial good 
response of patients to platinum-based 
chemotherapies, there has been little 
improvement in the survival rates 
for over three decades. About 65% 
of women with epithelial ovarian 
cancer will die within five years of 
their diagnosis [1]. Early-stage ovarian 
cancers are often asymptomatic and 
the recognised signs and symptoms, 
even of late-stage disease, are vague. 
Consequently, most patients are 
diagnosed with advanced disease, and 
it seems unlikely that symptoms alone 
could help to improve the proportion 
of tumours that are diagnosed at 
earlier, more treatable stages.
Unfortunately, there are no 
effective biomarkers that can identify 
early-stage disease and no reliable 
prognostic markers for predicting 
clinical response and guiding 
treatment regimes. Furthermore, 
there remains intense debate about 
the cellular origins, precursor lesions, 
and histological classification of the 
disease. With so many unknowns, it is 
perhaps not surprising that progress 
in reducing mortality in women 
diagnosed with ovarian cancer has 
been so limited.
Two New Translational Research 
Studies
There is continued hope that the 
most recent scientific advances and 
discoveries will have the potential 
to affect patient care (translational 
research). For example, the last decade 
has seen revolutionary developments 
in the approaches used to characterise 
solid tumours at the molecular level. 
For some cancer types, the molecular 
characterisation of tumours has led to 
better strategies for predicting disease 
outcome, so that treatments can be 
targeted more effectively, and to the 
development of new therapies. Many 
of these approaches have been tried 
and tested for ovarian cancer too, but 
they have so far failed to deliver on 
the anticipation of a new biomarker 
or gene signature that can improve 
our understanding of the disease. Two 
studies published in PLoS Medicine,
one in December 2008 and one in the 
current issue, shed some much needed 
light on the clinical challenge of 
ovarian cancer.
Clinico-pathological heterogeneity 
in epithelial ovarian cancer. The
first study from Huntsman and 
colleagues [2] tackles the issue of 
clino-pathological heterogeneity in 
epithelial ovarian cancer. Scientists 
frequently refer to epithelial ovarian 
cancer as a single disease entity, even 
though it has been known for some 
time that this term describes a diverse 
group of tumours, each with different 
microscopic appearances and biological 
and genetic backgrounds. This diversity 
extends to clinical features of the 
disease; patients with different sub-
types of ovarian cancer can respond 
differently to the same treatments and 
have different prognoses associated 
with their disease [3–5]. Arguably, the 
single feature that ovarian cancers have 
in common is the site of diagnosis.
In order to define the different 
ovarian cancer sub-types at the 
molecular level, Huntsman and 
colleagues measured the expression of 
21 candidate protein markers in 500 
ovarian carcinomas representing the 
five main sub-types: high-grade serous, 
clear cell, endometrioid, mucinous, 
and low-grade serous. When the 
tumours were considered as a single 
phenotype, the investigators found 
ten biomarkers that were differentially 
expressed between early- and late-
stage cancers. However, none of these 
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Linked Research Articles
This Perspective discusses the following 
recent studies published in PLoS Medicine:
Crijns APG, Fehrmann RSN, de Jong S, 
Gerbens F, Meersma GJ, et al. (2009) 
Survival-related profile, pathways, and 
transcription factors in ovarian cancer. 
PLoS Med 6(2): e1000024. doi:10.1371/
journal.pmed.1000024
Ate van der Zee and colleagues analyze 
the gene expression profiles of ovarian 
cancer samples from 157 patients, and 
identify an 86-gene expression profile 
that seems to predict overall survival. 
Köbel M, Kalloger SE, Boyd N, McKinney
S, Mehl E, et al. (2008) Ovarian carcinoma 
subtypes are different diseases: 
Implications for biomarker studies. PLoS 
Med 5(12): e232. doi:10.1371/journal.
pmed.0050232
David Huntsman and colleagues describe 
the associations between biomarker 
expression patterns and survival in 
different ovarian cancer subtypes. They 
suggest that the management of ovarian 
cancer should reflect differences between 
these subtypes.
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markers varied with stage when this 
analysis was repeated after stratifying 
tumours by sub-type. Of the 21 
different biomarkers tested, 20 differed 
significantly between sub-types, adding 
to a growing body of evidence showing 
that ovarian cancer heterogeneity 
is reflective of divergent molecular 
pathways underlying the development 
of the disease (Figure 1).
Several hypotheses have been 
suggested as a biological basis for 
this heterogeneity, such as the 
uncommitted state of the ovarian 
surface epithelium, and more recently, 
evidence that ovarian carcinomas can 
arise from a variety of precursor cell 
populations. For example, synchronous 
endometriosis is commonly observed 
in endometrioid and clear cell 
carcinomas, suggesting that at least 
one-third of these tumour types are 
associated with this benign lesion [6]. 
More recently, it has been suggested 
that at least a sub-set of epithelial 
ovarian cancers originate in the 
fallopian tube. Expression of the 
TP53 tumour suppressor protein in 
both ovarian inclusion cysts and the 
fallopian tube fimbriae (the distal 
portion of the fallopian tube) suggests 
that both could represent the origin of 
high-grade serous ovarian carcinomas 
[7,8]. An emerging hypothesis is that 
all ovarian cortical inclusion cysts 
that give rise to high-grade serous 
ovarian carcinomas originate from the 
fallopian tube; but this hypothesis will 
be a challenge to prove or disprove, 
since the hormone and growth-factor 
rich microenvironment of the ovarian 
stroma is likely to induce phenotypic 
changes in any epithelial cells that 
become trapped within it [8].
Huntsman and colleagues also 
looked at associations with outcome 
in their 21-biomarker panel. They 
found nine markers that were 
associated with differences in patient 
survival when the entire cohort was 
considered; but only three markers 
continued to show an association 
after sub-type stratification. To some 
degree, these data need to be treated 
with caution. Although this probably 
represents the most comprehensive 
immunohistochemistry based 
biomarker study to be published for 
ovarian cancer, after stratification 
into five sub-groups the number of 
cases within each sub-group limits 
the power of the study to detect 
significant associations and increases 
the likelihood of finding false positive 
associations. These findings will need 
validation in independent sample sets 
before researchers can feel confident 
that some of these prognostic markers 
might be of genuine use clinically. 
The overarching message from 
Huntsman and colleagues’ study is 
that biomarker expression is more 
strongly associated with histological 
sub-type than it is with disease stage. 
Looking to the future implications of 
these findings, a molecular profiling 
strategy may one day be a necessary 
diagnostic step in the clinical 
management of different ovarian 
cancer sub-types prior to making 
decisions on how to treat a patient’s 
disease. A robust set of biomarkers in 
combination with universal guidelines 
for the classification of ovarian 
tumours will also be an essential 
feature of population-based studies 
of ovarian cancer that aim to identify 
any biomarker associated with any 
aspect of disease. There are additional 
impediments to the histological 
doi:10.1371/journal.pmed.1000025.g001
Figure 1. Histological and Molecular Heterogeneity in Epithelial Ovarian Cancers
Common genetic alterations vary between different epithelial ovarian cancer sub-types. 
Highlighted in red are genes/pathways commonly inactivated in tumours; highlighted in green 
are genes commonly activated or amplified in epithelial ovarian cancer tumour specimens. 
Hematoxylin and eosin stained sections show typical histological and architectural appearance 
of the high-grade serous, borderline serous, mucinous, clear cell, and endometrioid sub-types. 
Biomarkers listed are those found in the study by Huntsman and colleagues to be highly expressed 
(i.e., samples positive in over 60% of tumours, green arrow), or lowly expressed (red arrow) in each 
histological sub-type. Median Ki67 labelling indices (a measure of the proportion of proliferating 
cells in a tumour sample) are given in bold type.
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diagnosis of ovarian cancers that 
would benefit from such a molecular 
scoring system. For example, a 
proportion of ovarian cancers remain 
unclassified mainly because they are 
either undifferentiated or of mixed 
histology; and so biomarker profiling 
could provide an accurate method 
of differentiating tumours where 
the histopathological diagnoses are 
equivocal.
Gene expression profiling of 
ovarian cancers. The second study, 
by Crijns and colleagues [9], which is 
published in the current issue, takes a 
very different approach to the analysis 
of ovarian cancers (gene expression 
microarrays). Nevertheless, Crijns 
and colleagues’ study echoes the 
underlying theme of Huntsman and 
colleagues’ study in that the molecular 
analyses of tumours should be based 
on accurately defined histological 
sub-types of the disease. The use of 
gene expression profiling strategies 
to characterise human solid tumours 
was popularised after a study from 
van de Vijver and colleagues in 2002, 
which showed that gene expression 
signatures of breast cancers could 
be used to predict clinical outcome 
[10]. Since then, a similar approach 
has been used to characterise a 
multitude of different tumour types 
with varying degrees of success. For 
ovarian cancer, there are in excess 
of 40 published reports describing 
gene expression microarray analyses 
in ovarian tumours. However, a meta-
analysis of 17 of these studies, which 
included 386 ovarian cancers, showed 
that there was very limited overlap 
between studies in the genes that were 
identified as “important” in ovarian 
cancer development [11].
This meta-analysis highlights many 
of the challenges of gene expression 
microarray studies and indicates why, 
most of the time, they have been 
unsuccessful in either identifying 
novel molecular targets of tumour 
development or gene signatures 
that can be used to predict clinical 
outcome. In a recent review, Tinker et 
al. neatly summed up many of these 
challenges [12]. The main issues relate 
to: the quality in the study design (e.g., 
using a well-defined phenotype that 
considers and adjusts for confounding 
factors); the quality of the experimental 
design (e.g., the microarray platform 
used and the tissues from which 
nucleic acids are extracted); and the 
statistical power of the study to detect 
meaningful effects after the analysis of 
several thousands of variables.
Crijns and colleagues’ study is 
impressive in that it takes into account 
many of the potential pitfalls of gene 
expression microarray studies. As a 
result, it establishes a good chance 
of finding something meaningful. 
The main aim is clear and focused, 
asking the question, “Is there a genetic 
signature in advanced stage serous 
ovarian cancers that can predict 
survival after a diagnosis of the 
disease?” The study, which comprises 
157 tumours, is substantially larger 
than most other studies of ovarian 
cancer that use a similar approach, 
but the selection of a specific tumour 
sub-type is perhaps the most significant 
strength in the study design. The 
authors identify a limited set of 
genetic events from the analysis of 
approximately 35,000 probes on a 
microarray, which provides a molecular 
signature that can distinguish between 
patients with good and bad prognosis. 
Using a cross validation approach that 
trained the data on 90% of the cases 
and tested the survival predictors on 
the remaining 10%, they were able to 
stratify patients into a low-risk group 
(mean survival time 41 month) and a 
high-risk group (mean survival time 
19 months). This was statistically 
significant even after adjustment 
following permutation testing, 
suggesting it is unlikely that this result 
is due to over-fitting of the data.
Next Steps
For studies such as those described by 
Huntsman and colleagues and Crijns 
and colleagues, there is a critical need 
to validate the findings in independent 
sample sets. This validation can be 
performed as part of an intra-study 
design, in which a second set of cases 
are evaluated by the same investigators 
using a similar experimental 
methodology; or, as Crijns and 
colleagues have done, by using publicly 
available data from one or more 
completely independent studies. Crijns 
and colleagues used published data 
from an expression microarray analysis 
of 118 primary serous ovarian cancers. 
Even though this analysis had been 
performed on a different microarray 
platform, the investigators were able to 
identify a 57-gene signature, which was 
a sub-set of their 86-gene signature, that 
was able to predict which patients fell 
into the low- and high-risk prognostic 
groups they had defined.
The findings of both of the studies 
described in this Perspective are very 
encouraging, given previous attempts 
to identify prognostic markers or 
molecular signatures for ovarian 
cancer. Much more extensive follow-up 
is now needed, requiring multi-centre 
collaborations and agreement on 
the most appropriate study designs, 
which will need to consider the 
challenges surrounding experimental 
methodology, quality control, statistical 
power, and (of course) phenotypic 
heterogeneity. As is so often the case, 
breast cancer research in this area is 
at a much more advanced stage and 
represents something of a paradigm. 
There is now good evidence that gene 
expression signatures that predict 
prognosis in breast cancer, generated 
from a multitude of independent 
studies, can be validated in multi-
centre studies [13,14]. This has led 
to the initiation of two prospective 
randomised clinical trials to test the 
efficacy of using expression profiling in 
clinical practice [15].
Could these molecular tools 
ultimately be used to guide 
personalised treatment for patients 
with ovarian cancer? The work of 
Huntsman and Crijns and colleagues, 
and the example of breast cancer, 
certainly suggests that this may be 
feasible—but only if ovarian cancers are 
appropriately classified. The first step 
would seem to be to get an agreement 
amongst researchers and clinicians 
about what this classification comprises. 
Only then does it seem likely that 
inroads can be made into the mortality 
statistics that so consistently define this 
disease. 
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